by The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a 0 million (CHF870 million) cash payment. A possible performance-related payment of 0 million could be added to the purchase price, the Swiss AWP financial news agency reported. The divested business generated sales of 0 million in the first half of 2018. It includes approximately 300 products and development projects. A Novartis spokesman refused to comment on whether other parts of the Sandoz portfolio in the United States were
Topics:
Swissinfo considers the following as important: 3) Swiss Markets and News, Aurobindo Pharma, Featured, Latest News, newsletter, Novartis, PharmaDerm, Sandoz US
This could be interesting, too:
Guillermo Alcala writes USD/CHF slides to test 0.8645 support with US inflation data on tap
Swissinfo writes Swiss central bank posts CHF62.5bn profit
Nachrichten Ticker - www.finanzen.ch writes Trump-Faktor und Marktbedingungen könnten für neuen Bitcoin-Rekord sorgen
Charles Hugh Smith writes Is Social Media Actually “Media,” Or Is It Something Else?
The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term.
Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a $900 million (CHF870 million) cash payment.
A possible performance-related payment of $100 million could be added to the purchase price, the Swiss AWP financial news agency reported.
The divested business generated sales of $600 million in the first half of 2018. It includes approximately 300 products and development projects.
A Novartis spokesman refused to comment on whether other parts of the Sandoz portfolio in the United States were still for sale.
750 employees affected
The production facilities in Wilson, North Carolina, as well as in Hicksville and Melville, New York, will also be transferred to Aurobindo.
In this context, approximately 750 employees and the sales force of the dermatology business PharmaDerm will be transferred to the Indian company upon completion of the transaction.
Novartis said the transaction is expected to close during 2019.
Focus on complex generics
Sandoz will focus instead on complex generics, value-added medicines and biosimilars.
The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. “With this transaction, we are focusing our business,” Sandoz CEO Richard Francis was quoted as saying.
The Sandoz portfolio will remain “strong” even after the transaction, according to the company statement. It includes injectables, respiratory products and ophthalmics.
Tags: Aurobindo Pharma,Featured,Latest news,newsletter,Novartis,PharmaDerm,Sandoz US